Axsome Therapeutics Reports Q3 2026 Results, Revenue Growth

Axsome Therapeutics 3Q Loss/Shr 25c >AXSM

Axsome Therapeutics Q3 2026 net loss narrows 73% year over year to $12.88 million Axsome Therape

Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growthAUVELITY® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growthSUNOSI® 3Q 2026 net product revenue of $48.2 million, representing 47% year-over-year growthSYMBRAVO® 3Q 2026 net p…

*--Earnings Flash (AXSM) Axsome Therapeutics Posts Q3 Loss $0.25 a Share, vs. FactSet Est of $0.63 Loss

Axsome reported third-quarter 2026 net product revenue of $259.7M, up 52% year over year. AUVELITY sales were $207.6M, SUNOSI revenue was $48.2M and SYMBRAVO sales were $3.9M; each product's sales grew year over year.Material DetailsContext by AI AnalystThis is a current-quarter commercial update s…

Nov 02 (Reuters) - Axsome Therapeutics Q3 operating income USD -11.068 million.

Axsome Therapeutics verringert Nettoverlust im dritten Quartal 2026 gegenüber Vorjahr um 73 Prozent

Axsome, nel terzo trimestre 2026 perdita netta in calo del 73% su anno a 12,88 milioni di dollari; r